<DOC>
	<DOCNO>NCT01790737</DOCNO>
	<brief_summary>The purpose study determinate efficacy safety 3-drug induction treatment ( RVD ; lenalidomide plus bortezomib plus dexamethasone ) follow randomize autologous stem cell mobilization , autologous stem cell transplantation lenalidomide maintenance . Primary endpoint immunophenotypic remission rate.During randomize mobilization phase two active comparator arm Cyclophosphamide ( CY ) 2g/m2 + Granylocyte-colony stimulating factor ) G-CSF vrs G-CSF compare regard efficacy , cost safety .</brief_summary>
	<brief_title>First Line Treatment Trial Multiple Myeloma , Finnish Myeloma Group- Multiple Myeloma 02</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>write informed consent symptomatic , previously untreated International Stating System ( ISS ) 13 myeloma measurable disease WHO perf status 03 eligible ASCT previously treat peripheral neuropathy gr &gt; /= 2 significant hepatic dysfunction severe cardiac dysfunction severe renal failure dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>myeloma , stem cell mobilization , autologous stem cell transplantation</keyword>
	<keyword>induction treatment , maintenance treatment</keyword>
</DOC>